Inhibition of the renin-angiotensin system and chronic kidney disease

International Urology and Nephrology

Volumn 40, Issue 4, 2008, Pages 1015-1025

  Siamopoulos, Kostas C ^a   Kalaitzidis, Rigas G ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin II receptor antagonists; Chronic kidney disease; Renin inhibitor

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; IRBESARTAN; LISINOPRIL; LOSARTAN; NISOLDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN; VERAPAMIL;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR FUNCTION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY FUNCTION; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; KIDNEY FAILURE, CHRONIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 56349108016     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11255-008-9424-x     Document Type: Review

References (94)

1. USRD 2006 ADR/reference tables. Available at: http://www.usrds.org/ reference_2006.htm 2008
2. El-Nahas M (2005) The global challenge of chronic kidney disease. Kidney Int 68:2918-2929
3. Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, Neaton JD (2006) Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 17:1444-1452
4. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE (1995) Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25:587-594
5. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 352:1252-1256
6. Schaeffner ES, Kurth T, Bowman TS, Gelber RP, Gaziano JM (2007) Blood pressure measures and risk of chronic kidney disease in men. Nephrol Dial Transplant 4:1246-1251
7. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:1-12
8. Willenheimer R, Dahlof B, Rydberg E et al (1999) AT1-receptor blockers in hypertension and heart failure: Clinical experience and future directions. Eur Heart J 20:997-1008
9. Karalliedde J, Viberti G (2006) Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes. J Hum Hypertens 20:239-253
10. Zanchetti A, Ruilope LM (2002) Antihypertensive treatment in patients with type-2 diabetes mellitus: What guidance from recent controlled randomized trials? J Hypertens 20:2099-2110
11. Mancia G, De BG, Dominiczak A, Cifkova R et al (2007) 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105-1187
12. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857-1863
13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869
14. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF (1993) Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 118:129-138
15. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G (1998) Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 53:1209-1216
16. Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941-1951
17. Suissa S, Hutchinson T, Brophy JM, Kezouh A (2006) ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 69:913-919
18. Covic A, Gusbeth-Tatomir P, Goldsmith DJ (2007) Current dilemmas in inhibiting the renin-angiotensin system: Do not forget real life. Int Urol Nephrol 39:571-576
19. Rossing P, Parving HH, de Zeeuw D (2006) Renoprotection by blocking the RAAS in diabetic nephropathy-fact or fiction? Nephrol Dial Transplant 21:2354-2357
20. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005) Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: Systematic review and meta-analysis. Lancet 366:2026-2033
21. Luft FC, Weinberger MH (2007) Antihypertensive therapy with aliskiren. Kidney Int. doi: 10.1038/sjki5002732
22. Luther RR, Glassman HN, Boger RS (1991) Renin inhibitors in hypertension. Clin Nephrol 36:181-186
23. Muller DN, Luft FC (2006) Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 1:221-228
24. Oh BH (2007) Aliskiren, the first in a new class of direct renin inhibitors for hypertension: Present and future perspectives. Expert Opin Pharmacother 8:2839-2849
25. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Müller DN (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46:569-576
26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456-1462
27. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH (2000) Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 23:1725-1730
28. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359-364
29. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 334:939-945
30. Parving HH, Hovind P, Rossing K (2001) Evolving strategies for renoprotection: Diabetic nephropathy. Curr Opin Nephrol Hypertens 10:515-522
31. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356-360
32. Nelson RG, Knowler WC, Pettitt DJ, Saad MF, Charles MA, Bennett PH (1991) Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 151:1761-1765
33. Bigazzi R, Bianchi S, Baldari D, Campese VM (1998) Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16:1325-1333
34. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G (2004) Clinical significance of renal function in hypertensive patients at high risk: Results from the INSIGHT trial. Arch Intern Med 164:2459-2464
35. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, HOPE Study Investigators (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421-426
36. Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD (1999) Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: Five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 19:617-624
37. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K (2000) Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35:898-903
38. Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association councils on kidney in cardiovascular disease high blood pressure research, clinical cardiology and epidemiology and prevention. Circulation 108:2154-2169
39. Wachtell K, Ibsen H, Olsen MH et al (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE study. Ann Intern Med 139:901-906
40. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342:145-153
41. The EUCLID Study Group (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787-1792
42. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128:982-988
43. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354:131-140
44. Berl T, Hunsicker LG, Lewis JB et al (2003) Cardiovascular outcomes in the Irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:542-549
45. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878
46. Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106:672-678
47. Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30-48
48. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH (2002) Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 17:1413-1418
49. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R (2007) Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 25:1921-1926
50. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH (2005) Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68:1190-1198
51. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005) Additional antiproteinuric effect of ultrahigh dose candesartan: A double-blind, randomized, prospective study. J Am Soc Nephrol 16:3038-3045
52. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D (2002) Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62:1020-1025
53. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN (2008) Systematic review: Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148:16-29
54. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952-1961
55. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I (2007) Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: Results of the IMPROVE trial. Kidney Int 72:879-885
56. Kincaid-Smith P, Fairley K, Packham D (2002) Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 17:597-601
57. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361:117-124
58. Kincaid-Smith P, Fairley KF, Packham D (2004) Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: Effects on proteinuria and blood pressure. Nephrol Dial Transplant 19:2272-2274
59. Kidney Disease Outcome Quality Initiative (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43(5 Suppl 1):S65-S230
60. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358(23):2433-2446
61. Toto R, Palmer BF (2007) Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease. Am J Nephrol 28:372-380
62. Teo K, Yusuf S, Sleight P et al (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148:52-61
63. Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: Where are we now, and where are we going? J Hypertens 24:243-256
64. Brewster UC, Setaro JF, Perazella MA (2003) The renin-angiotensin-aldosterone system: Cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326:15-24
65. Stanton A (2003) Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 3:389-394
66. Stanton A, Jensen C, Nussberger J, O'Brien E (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42:1137-1143
67. Stanton A (2003) Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4:6-10
68. Wood JM, Maibaum J, Rahuel J et al (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308:698-705
69. Drummond W, Munger MA, Rafique EM (2007) Antihypertensive efficacy of the oral direct Renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 9:742-750
70. O'Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A (2007) Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49:276-284
71. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial. Lancet 370:221-229
72. Berne C, Pollare T, Lithell H (1991) Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14(Suppl 4):39-47
73. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB Jr, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW 3rd, Young JB, Probstfield J (1996) Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 131:350-355
74. Baraldi A, Ballestri M, Rapanà R, Lucchi L, Borella P, Leonelli M, Furci L, Lusvarghi E (1998) Acute renal failure of medical type in an elderly population. Nephrol Dial Transplant 13(Suppl 7):25-29
75. Lboz KK, Shenfield GM (2005) Drug combinations and impaired renal function-the 'triple whammy'. Br J Clin Pharmacol 59:239-243
76. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK (1999) Captopril for prevention of contrast-induced nephropathy in diabetic patients: A randomised study. Indian Heart J 51:521-526
77. Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 160:685-693
78. Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, Esi E (2006) Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 104:c20-c27
79. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL (2003) The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg 3:98-103
80. Mahajan S, Tiwari S, Bhowmik D, Agarwal SK, Tiwari SC, Dash SC (2006) Factors affecting the outcome of acute renal failure among the elderly population in India: A hospital based study. Int Urol Nephrol 38:391-396
81. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF (2008) The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. doi: 10.1007/s11255-008-9368-1
82. Gami AS, Garovic VD (2004) Contrast nephropathy after coronary angiography. Mayo Clin Proc 79:211-219
83. Maeder M, Klein M, Fehr T, Rickli H (2004) Contrast nephropathy: Review focusing on prevention. J Am Coll Cardiol 44:1763-1771
84. Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. JAMA 289:2560-2572
85. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J (2000) Preserving renal function in adults with hypertension and diabetes: A consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661
86. Koshy S, Bakris GL (2000) Therapeutic approaches to achieve desired blood pressure goals: Focus on calcium channel blockers. Cardiovasc Drugs Ther 14:295-301
87. Wright JT Jr, Bakris G, Greene T et al (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288:2421-2431
88. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, AIPRD Study Group (2003) Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 139:244-252
89. Schrier RW, Estacio RO, Mehler PS, Hiatt WR (2007) Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: A summary of the ABCD trial. Nat Clin Pract Nephrol 3:428-438
90. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877-884
91. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS (2005) The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142:342-351
92. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA (1987) Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed) 294:1443-1447
93. Brenner BM (2003) Retarding the progression of renal disease. Kidney Int 64:370-378
94. Covic A, Gusbeth-Tatomir P, Goldsmith DJ (2007) Current dilemmas in inhibiting the renin-angiotensin system: Do not forget real life. Int Urol Nephrol 39(2):571-576